The latest drug to receive a recommendation for conditional marketing authorization (CMA) from the European Medicines Agency is a new treatment for soft tissue sarcoma, Lilly’s Lartruvo (olaratumab), which when used with doxorubicin has been shown to improve survival compared with the older drug alone.
Eli Lilly & Co.said that the opinion from the EMA’s scientific committee, the CHMP, was...






